Acquisitions28 Jul 2025, 12:35 pm
3B BlackBio Dx Ltd Acquires Coris Holding SRL for £2.765 Million
AI Summary
3B BlackBio Dx Ltd, along with its subsidiary TRUPCR® Europe Limited, has entered into a definitive agreement with Avacta Group Plc, London to acquire all the shares of Coris Holding SRL for an upfront cash consideration of £2.15 Million with an earn-out based on future business performance, of up to £0.615 Million. The acquisition will strengthen 3B's position in the IVD market globally and allow for faster growth in untapped markets. The acquisition is expected to be completed by 10th September 2025.
Key Highlights
- 3B BlackBio Dx Ltd and TRUPCR® Europe Limited jointly acquire 100% stake in Coris Holding SRL, Belgium
- Coris Bioconcept SRL is a leading European manufacturer of IVD test kits, primarily focusing on antimicrobial resistance (AMR) diagnostics
- The acquisition will strengthen 3B's position in the IVD market globally and allow for faster growth in untapped markets
- The acquisition is expected to be completed by 10th September 2025
- Coris holds a global monopoly for the HAT Sero K-SeT lateral flow test for detecting antibodies specific to Trypanosoma brucei gambiense in human whole blood, serum or plasma